

Marian J E Mourits

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8322926/publications.pdf>

Version: 2024-02-01

46
papers

1,642
citations

394390

19
h-index

302107

39
g-index

48
all docs

48
docs citations

48
times ranked

2101
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 763-771.	10.7	280
2	Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6890-6898.	1.6	214
3	The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy. <i>Journal of Clinical Oncology</i> , 2006, 24, 3576-3582.	1.6	186
4	CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. <i>European Journal of Cancer</i> , 2016, 60, 1-11.	2.8	125
5	Early salpingectomy (TUBectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. <i>BMC Cancer</i> , 2015, 15, 593.	2.6	88
6	Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. <i>European Journal of Cancer</i> , 2016, 61, 137-145.	2.8	64
7	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 714-724.	7.0	51
8	Endometrial Cancer Risk in Women With Germline <i>BRCA1</i> or <i>BRCA2</i> Mutations: Multicenter Cohort Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1203-1211.	6.3	44
9	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	5.0	41
10	Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. <i>European Journal of Cancer</i> , 2017, 84, 159-167.	2.8	40
11	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 51.e1-51.e17.	1.3	34
12	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	2.9	33
13	Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. <i>European Journal of Cancer</i> , 2015, 51, 400-408.	2.8	32
14	Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy. <i>Maturitas</i> , 2018, 111, 69-76.	2.4	30
15	Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in <i>BRCA1/2</i> Pathogenic Variant Carriers. <i>JAMA Oncology</i> , 2021, 7, 1203.	7.1	27
16	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1879-1891.	1.6	25
17	Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Prevention Research</i> , 2012, 5, 1291-1297.	1.5	24
18	A Survey of Female Sexual Functioning in the General Dutch Population. <i>Journal of Sexual Medicine</i> , 2017, 14, 937-949.	0.6	23

#	ARTICLE	IF	CITATIONS
19	Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers. <i>Modern Pathology</i> , 2013, 26, 572-578.	5.5	22
20	Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2015, 33, 2553-2562.	1.6	22
21	Stopping ovarian cancer screening in <i>BRCA1/2</i> mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens. <i>Maturitas</i> , 2015, 80, 318-322.	2.4	19
22	Bone mineral density and fractures after surgical menopause: systematic review and meta-analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1525-1535.	2.3	18
23	Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial. <i>Gynecologic Oncology</i> , 2022, 164, 265-270.	1.4	18
24	Surgical volume and conversion rate in laparoscopic hysterectomy: does volume matter? A multicenter retrospective cohort study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 1021-1026.	2.4	16
25	Proven non-carriers in BRCA families have an earlier age of onset of breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 2101-2106.	2.8	15
26	Determinants of health-related quality of life in elderly ovarian cancer patients: The role of frailty and dependence. <i>Gynecologic Oncology</i> , 2019, 153, 610-615.	1.4	12
27	Normal vaginal microbiome in women with primary Sjögren's syndrome-associated vaginal dryness. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 707-709.	0.9	12
28	Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female <i>BRCA</i> Mutation Carriers in the Netherlands. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2482-2491.	2.5	11
29	Small RNA sequencing reveals a comprehensive miRNA signature of <i>BRCA1</i> -associated high-grade serous ovarian cancer. <i>Journal of Clinical Pathology</i> , 2016, 69, 979-985.	2.0	11
30	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. <i>European Journal of Cancer</i> , 2021, 148, 124-133.	2.8	11
31	Probability of detecting germline <i>BRCA1/2</i> pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. <i>Gynecologic Oncology</i> , 2022, 164, 221-230.	1.4	11
32	Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, 360-367.	1.4	10
33	Experiences of patients and health care professionals on the quality of telephone follow-up care during the COVID-19 pandemic: a large qualitative study in a multidisciplinary academic setting. <i>BMJ Open</i> , 2022, 12, e058361.	1.9	10
34	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMONY Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	1.0	9
35	PREsurgery thoughts – thoughts on prehabilitation in oncologic gynecologic surgery, a qualitative template analysis in older adults and their healthcare professionals. <i>Disability and Rehabilitation</i> , 2022, 44, 5930-5940.	1.8	9
36	Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer. <i>PLoS ONE</i> , 2017, 12, e0169673.	2.5	8

#	ARTICLE	IF	CITATIONS
37	Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications. <i>European Journal of Surgical Oncology</i> , 2022, 48, 896-902.	1.0	7
38	Oral Contraceptive Use in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Absolute Cancer Risks and Benefits. <i>Journal of the National Cancer Institute</i> , 2022, 114, 540-552.	6.3	7
39	The association between cancer family history and ovarian cancer risk in <i>BRCA1/2</i> mutation carriers: can it be explained by the mutation position?. <i>European Journal of Human Genetics</i> , 2018, 26, 848-857.	2.8	5
40	Ovarian cancer in <i>BRCA1/2</i> mutation carriers: The impact of mutation position and family history on the cancer risk. <i>Maturitas</i> , 2015, 82, 197-202.	2.4	4
41	Outcome of ovarian cancer after breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2016, 115, 1174-1178.	6.4	4
42	Risk assessment for postoperative outcomes in a mixed hospitalized gynecological population by the Dutch safety management system (Veiligheidsmanagementsysteem, VMS) screening tool "frail elderly". <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 465-473.	1.7	3
43	Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups. <i>Familial Cancer</i> , 2023, 22, 1-11.	1.9	3
44	Cancer worry among <i>BRCA1/2</i> pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors. <i>Supportive Care in Cancer</i> , 2022, 30, 3409-3418.	2.2	1
45	Survival benefit of epithelial ovarian cancer in hormone replacement therapy users: Could it be explained by socio-economic status?. <i>Maturitas</i> , 2016, 86, 26-27.	2.4	0
46	Preoperative physical activity and frailty in older patients undergoing cancer surgery "PREsurgery study. <i>Journal of Geriatric Oncology</i> , 2022, 13, 384-387.	1.0	0